Matthew Barcus
Stock Analyst at Chardan Capital
(2.24)
# 2,657
Out of 4,876 analysts
21
Total ratings
20.83%
Success rate
18.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Barcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZURA Zura Bio | Maintains: Buy | $12 → $10 | $1.05 | +852.38% | 3 | Mar 26, 2025 | |
| QURE uniQure | Maintains: Buy | $45 → $27 | $13.86 | +94.81% | 4 | Jun 22, 2023 | |
| XLO Xilio Therapeutics | Reiterates: Buy | $7 | $0.68 | +936.58% | 3 | May 30, 2023 | |
| IMVT Immunovant | Maintains: Buy | $21 → $32 | $16.10 | +98.76% | 4 | May 23, 2023 | |
| PPBT Purple Biotech | Reiterates: Buy | $220 | $2.30 | +9,465.22% | 3 | May 17, 2023 | |
| ANIX Anixa Biosciences | Reiterates: Buy | $9 | $3.22 | +179.50% | 3 | Apr 18, 2023 | |
| IMNM Immunome | Maintains: Buy | $9 → $8 | $8.77 | -8.78% | 1 | Mar 17, 2023 |
Zura Bio
Mar 26, 2025
Maintains: Buy
Price Target: $12 → $10
Current: $1.05
Upside: +852.38%
uniQure
Jun 22, 2023
Maintains: Buy
Price Target: $45 → $27
Current: $13.86
Upside: +94.81%
Xilio Therapeutics
May 30, 2023
Reiterates: Buy
Price Target: $7
Current: $0.68
Upside: +936.58%
Immunovant
May 23, 2023
Maintains: Buy
Price Target: $21 → $32
Current: $16.10
Upside: +98.76%
Purple Biotech
May 17, 2023
Reiterates: Buy
Price Target: $220
Current: $2.30
Upside: +9,465.22%
Anixa Biosciences
Apr 18, 2023
Reiterates: Buy
Price Target: $9
Current: $3.22
Upside: +179.50%
Immunome
Mar 17, 2023
Maintains: Buy
Price Target: $9 → $8
Current: $8.77
Upside: -8.78%